qbd Latest News

A new report by visiongain, a London-based business information company, predicts that world revenues for antibacterial drugs will reach $43.81bn in 2016.

A new report by visiongain predicts that revenues for disease-modifying treatments for multiple sclerosis (MS) will rise to $15.8bn annually in 2015. That analysis appears in Multiple Sclerosis Treatment: World Drug Market 2012-2022.

A new report by visiongain, a London-based business information provider, predicts that the global medical device contract manufacturing revenues will reach $95.7bn in 2021.

Visiongain predicts that world revenues for rheumatoid arthritis drugs will rise strongly between 2011 and 2021. This market will grow to reach $17.3bn in 2015. The rheumatoid arthritis drugs market generated $12.7bn in 2010.

A new report by visiongain predicts that the global companion diagnostics market will be worth $3.45bn by 2015. The market generated sales of $1.30bn in 2010, according to Companion Diagnostics: World Market Outlook 2011-2021, published in August.

A new report by visiongain, a London-based business information company, predicts that global pharmacovigilance spending will be worth $15.46bn by 2015. The market was worth just under $12bn in 2010.

METTLER TOLEDO has scheduled the 18th Annual International Process Development Conference (IPDC) for September 25-29, 2011 at the Park Hotel in picturesque Weggis, Switzerland.

METTLER TOLEDO has scheduled the 18th Annual International Process Development Conference (IPDC) for September 25-29, 2011 at the Park Hotel in picturesque Weggis, Switzerland.

Peptide Synthesis is naturally subject to a wide range of influences, such as reaction temperature, solvent, catalyst, as well as concentrations of the substrate and reagent.

METTLER TOLEDO will attend the 2010 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting to discuss collaborative research carried out with pharmaceutical scientists.